complement 3 glomerulopathy
Rare disease · 2025–2025
1decision
1medicine
1carried consumer input
2individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| iptacopan Treatment of adults with complement 3 glomerulopathy (C3G) with either native kidneys or disease recurrence following a kidney transplant. | Nov 2025 | Not recommended | 2 individuals Kidney Health Australia · Transplant Australia |
Who spoke
Kidney Health Australia · Transplant Australia
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 0 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| iptacopanIptacopan for treating complement 3 glomerulopathy (terminated appraisal) | TA1102 | terminated | 2025-10 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.